Valuation: Quest PharmaTech Inc.

Market Cap 4.23M 3.02M 2.63M 2.49M 2.26M 290M 4.25M 29.65M 11.45M 147M 11.35M 11.1M 471M P/E 2025
-3.29x
P/E 2026 1.18x
Enterprise Value 5.21M 3.72M 3.25M 3.07M 2.79M 357M 5.24M 36.57M 14.12M 182M 14M 13.69M 581M EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
83.12%
Yield 2025 *
-
Yield 2026 -
1 day+25.00%
1 week+25.00%
Current month+25.00%
1 month+25.00%
3 months-28.57%
6 months-16.67%
Current year-28.57%
1 week 0.02
Extreme 0.025
0.02
1 month 0.02
Extreme 0.02
0.02
Current year 0.02
Extreme 0.02
0.04
1 year 0.02
Extreme 0.02
0.05
3 years 0.02
Extreme 0.015
0.07
5 years 0.02
Extreme 0.015
0.16
10 years 0.02
Extreme 0.015
0.32
Manager TitleAgeSince
Chief Executive Officer - 2004-06-16
Director of Finance/CFO - 2004-12-31
Director TitleAgeSince
Director/Board Member - 2004-06-16
Chairman - 2021-07-04
Director/Board Member - 2021-07-04
Date Insider Type Main position Quantity % Market Cap. Importance
12/12/25 OtherCompany 0 0% -
10/21/25 Other

Chief Executive Officer

1,000,000 0.5913%
10/21/25 Other

Chief Executive Officer

300,000 0.1774%
Change 5-day change 1-year change 3-year change Capi.($)
+25.00%+25.00%-37.50%-58.33% 3.03M
+1.23%+1.30%-0.69%+9.57% 45.91B
+0.23%+4.85%+44.23%+27.27% 44.25B
+0.52%-5.17%+340.58%+520.09% 41.99B
+1.55%+0.70%+8.03%+76.45% 39.58B
+1.75%-1.53%+12.22%+41.11% 31.08B
-0.20%+4.93%+25.35%+119.72% 17.21B
-3.49%-8.35% - - 16.27B
+2.92%+8.37%+22.73%+38.87% 14.96B
-2.45%+6.38%-1.99%-35.16% 13.42B
Average +2.71%+1.38%+45.88%+82.18% 26.47B
Weighted average by Cap. +0.59%+0.68%+71.15%+120.61%

Financials

2025 2026
Net sales - -
Net income -1.8M -1.29M -1.12M -1.06M -964K -123M -1.81M -12.63M -4.88M -62.79M -4.83M -4.73M -201M 5M 3.57M 3.11M 2.95M 2.67M 343M 5.03M 35.06M 13.54M 174M 13.42M 13.12M 557M
Net Debt 795K 568K 495K 469K 425K 54.48M 799K 5.57M 2.15M 27.72M 2.13M 2.09M 88.63M 986K 704K 614K 581K 527K 67.55M 991K 6.91M 2.67M 34.36M 2.65M 2.59M 110M
Logo Quest PharmaTech Inc.
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Employees
-
Date Price Change Volume
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!